Off-label prescription of antineoplastic drugs: An Italian prospective, observational, multicenter survey

Fausto Roila, Enzo Ballatori, Roberto Labianca, Filippo De Braud, Karen Borgonovo, Olga Martelli, Ciro Gallo, Angelo Tinazzi, Francesco Perrone

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aims and background. An appropriate use of drugs should follow the registered indications. Different reasons can induce oncologists to prescribe drugs off-label. The aim of this study was to describe incidence and characteristics of these prescriptions in Italy. Methods. Patients submitted to chemotherapy in 15 Italian oncology centers were evaluated for two randomized non-consecutive days of two weeks in May 2006. Results. The study enrolled 644 patients receiving 1,053 drugs. Overall, 199 of 1053 (18.9%) prescriptions were off-label. In 92 of 199 cases (46.2%), the drugs were used for a neoplasm for which they were not approved, but there was scientific evidence (one or more randomized clinical trials or more phase II studies published in a major oncology journal) justifying the prescription. In 27 cases (13.6%), the drugs were prescribed for a rare neoplasm (cisplatin and gemcitabine in mesothelioma). In 20/21 cases (10.1%/10.5%), drugs were used in association/alone in contrast with the approved use (capecitabine in association in colorectal cancer). In 28/11 cases (14.0%/5.6%), the drugs were used in lines of chemotherapy subsequent/previous to that approved. Conclusions. Off-label use of antineoplastic drugs, in this observational survey, represents less than 20% of the prescriptions, and most of them are based on scientific evidence of efficacy.

Original languageEnglish
Pages (from-to)647-651
Number of pages5
JournalTumori
Volume95
Issue number6
Publication statusPublished - Nov 2009

Fingerprint

Prescription Drugs
Antineoplastic Agents
Prescriptions
Pharmaceutical Preparations
gemcitabine
Off-Label Use
Drug Therapy
Mesothelioma
Surveys and Questionnaires
Italy
Cisplatin
Colorectal Neoplasms
Neoplasms
Randomized Controlled Trials
Incidence

Keywords

  • Antineoplastic agents
  • Chemotherapy
  • Off-label

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Roila, F., Ballatori, E., Labianca, R., De Braud, F., Borgonovo, K., Martelli, O., ... Perrone, F. (2009). Off-label prescription of antineoplastic drugs: An Italian prospective, observational, multicenter survey. Tumori, 95(6), 647-651.

Off-label prescription of antineoplastic drugs : An Italian prospective, observational, multicenter survey. / Roila, Fausto; Ballatori, Enzo; Labianca, Roberto; De Braud, Filippo; Borgonovo, Karen; Martelli, Olga; Gallo, Ciro; Tinazzi, Angelo; Perrone, Francesco.

In: Tumori, Vol. 95, No. 6, 11.2009, p. 647-651.

Research output: Contribution to journalArticle

Roila, F, Ballatori, E, Labianca, R, De Braud, F, Borgonovo, K, Martelli, O, Gallo, C, Tinazzi, A & Perrone, F 2009, 'Off-label prescription of antineoplastic drugs: An Italian prospective, observational, multicenter survey', Tumori, vol. 95, no. 6, pp. 647-651.
Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O et al. Off-label prescription of antineoplastic drugs: An Italian prospective, observational, multicenter survey. Tumori. 2009 Nov;95(6):647-651.
Roila, Fausto ; Ballatori, Enzo ; Labianca, Roberto ; De Braud, Filippo ; Borgonovo, Karen ; Martelli, Olga ; Gallo, Ciro ; Tinazzi, Angelo ; Perrone, Francesco. / Off-label prescription of antineoplastic drugs : An Italian prospective, observational, multicenter survey. In: Tumori. 2009 ; Vol. 95, No. 6. pp. 647-651.
@article{f4109f8180894e7ab010e14350bdeda0,
title = "Off-label prescription of antineoplastic drugs: An Italian prospective, observational, multicenter survey",
abstract = "Aims and background. An appropriate use of drugs should follow the registered indications. Different reasons can induce oncologists to prescribe drugs off-label. The aim of this study was to describe incidence and characteristics of these prescriptions in Italy. Methods. Patients submitted to chemotherapy in 15 Italian oncology centers were evaluated for two randomized non-consecutive days of two weeks in May 2006. Results. The study enrolled 644 patients receiving 1,053 drugs. Overall, 199 of 1053 (18.9{\%}) prescriptions were off-label. In 92 of 199 cases (46.2{\%}), the drugs were used for a neoplasm for which they were not approved, but there was scientific evidence (one or more randomized clinical trials or more phase II studies published in a major oncology journal) justifying the prescription. In 27 cases (13.6{\%}), the drugs were prescribed for a rare neoplasm (cisplatin and gemcitabine in mesothelioma). In 20/21 cases (10.1{\%}/10.5{\%}), drugs were used in association/alone in contrast with the approved use (capecitabine in association in colorectal cancer). In 28/11 cases (14.0{\%}/5.6{\%}), the drugs were used in lines of chemotherapy subsequent/previous to that approved. Conclusions. Off-label use of antineoplastic drugs, in this observational survey, represents less than 20{\%} of the prescriptions, and most of them are based on scientific evidence of efficacy.",
keywords = "Antineoplastic agents, Chemotherapy, Off-label",
author = "Fausto Roila and Enzo Ballatori and Roberto Labianca and {De Braud}, Filippo and Karen Borgonovo and Olga Martelli and Ciro Gallo and Angelo Tinazzi and Francesco Perrone",
year = "2009",
month = "11",
language = "English",
volume = "95",
pages = "647--651",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Off-label prescription of antineoplastic drugs

T2 - An Italian prospective, observational, multicenter survey

AU - Roila, Fausto

AU - Ballatori, Enzo

AU - Labianca, Roberto

AU - De Braud, Filippo

AU - Borgonovo, Karen

AU - Martelli, Olga

AU - Gallo, Ciro

AU - Tinazzi, Angelo

AU - Perrone, Francesco

PY - 2009/11

Y1 - 2009/11

N2 - Aims and background. An appropriate use of drugs should follow the registered indications. Different reasons can induce oncologists to prescribe drugs off-label. The aim of this study was to describe incidence and characteristics of these prescriptions in Italy. Methods. Patients submitted to chemotherapy in 15 Italian oncology centers were evaluated for two randomized non-consecutive days of two weeks in May 2006. Results. The study enrolled 644 patients receiving 1,053 drugs. Overall, 199 of 1053 (18.9%) prescriptions were off-label. In 92 of 199 cases (46.2%), the drugs were used for a neoplasm for which they were not approved, but there was scientific evidence (one or more randomized clinical trials or more phase II studies published in a major oncology journal) justifying the prescription. In 27 cases (13.6%), the drugs were prescribed for a rare neoplasm (cisplatin and gemcitabine in mesothelioma). In 20/21 cases (10.1%/10.5%), drugs were used in association/alone in contrast with the approved use (capecitabine in association in colorectal cancer). In 28/11 cases (14.0%/5.6%), the drugs were used in lines of chemotherapy subsequent/previous to that approved. Conclusions. Off-label use of antineoplastic drugs, in this observational survey, represents less than 20% of the prescriptions, and most of them are based on scientific evidence of efficacy.

AB - Aims and background. An appropriate use of drugs should follow the registered indications. Different reasons can induce oncologists to prescribe drugs off-label. The aim of this study was to describe incidence and characteristics of these prescriptions in Italy. Methods. Patients submitted to chemotherapy in 15 Italian oncology centers were evaluated for two randomized non-consecutive days of two weeks in May 2006. Results. The study enrolled 644 patients receiving 1,053 drugs. Overall, 199 of 1053 (18.9%) prescriptions were off-label. In 92 of 199 cases (46.2%), the drugs were used for a neoplasm for which they were not approved, but there was scientific evidence (one or more randomized clinical trials or more phase II studies published in a major oncology journal) justifying the prescription. In 27 cases (13.6%), the drugs were prescribed for a rare neoplasm (cisplatin and gemcitabine in mesothelioma). In 20/21 cases (10.1%/10.5%), drugs were used in association/alone in contrast with the approved use (capecitabine in association in colorectal cancer). In 28/11 cases (14.0%/5.6%), the drugs were used in lines of chemotherapy subsequent/previous to that approved. Conclusions. Off-label use of antineoplastic drugs, in this observational survey, represents less than 20% of the prescriptions, and most of them are based on scientific evidence of efficacy.

KW - Antineoplastic agents

KW - Chemotherapy

KW - Off-label

UR - http://www.scopus.com/inward/record.url?scp=76349124677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76349124677&partnerID=8YFLogxK

M3 - Article

C2 - 20210223

AN - SCOPUS:76349124677

VL - 95

SP - 647

EP - 651

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -